医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Certara’s d3 Medicine Partners with the Australian Department of Defence to Audit the Nation’s Medical Countermeasures Preparedness

2017年04月05日 PM09:00
このエントリーをはてなブックマークに追加


 

PRINCETON, N.J.

Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that its d3 Medicine company has been selected to conduct a national audit of Australia’s medical countermeasures (MCM) product research and development (R&D) capabilities and capacity.

MCM include vaccines, therapeutics and diagnostics against chemical, biological and radiological threats; emerging infectious diseases and pandemics.

DST Group is partnering with d3 Medicine to assess and then optimize Australia’s MCM research, development and manufacturing capabilities.

“Thorough preparation is the best way to prevent a health crisis becoming a disaster,” said d3 Medicine President Craig R. Rayner, PharmD, MBA. “We are proud to help the Australian Government develop this comprehensive MCM preparedness approach, which is considered a priority under the Defence White Paper 2016.”

This new activity builds upon an initial audit conducted by d3 Medicine and DST Group in 2012. It aims to assess the nation’s current level of MCM knowledge, research, products, infrastructure and capability in both industry and academia.

d3 Medicine and DST Group continue to enhance their previously successful interactions. Together they have coordinated war gaming exercises with the Australian R&D community; proposed product development strategies for emergency situations; and collaborated with the Therapeutic Goods Administration to understand how an MCM emergency could inform the review and use of a MCM diagnostic and therapeutic solution.

d3 Medicine is well positioned to support the activities of DST Group. The company’s extensive global expertise in PK/PD modelling, pharmacometrics, asset due diligence, regulatory proficiency and clinical trials design are critical to the strategic guidance of this new initiative.

About Certara

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit www.certara.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170405005054/en/

CONTACT

Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief
Marketing Officer
or
Media Contact:
Rana
Healthcare Solutions
Lisa Osborne, 206-992-5245
lisa@ranahealth.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • MJC – Ancient Wisdom Meets Modern Channels
  • MJC——古老智慧与现代渠道的结合
  • Hallstar的新款光稳定剂AvoBrite®在交付卓越防晒产品的同时解决客户面临的监管挑战
  • ホールスターの新しい光安定剤AvoBrite®が、規制に関する課題を解決しつつ、卓越した光防御機能を提供
  • Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines